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ABSTRACT
The genus Alternaria contains several species of melanized hyphomycetes that cause opportunistic
human infections. The published literature contains 210 reported cases of human alternarioses between
1933 and the present day. The most frequent clinical manifestations are cutaneous and subcutaneous
infections (74.3%), followed by oculomycosis (9.5%), invasive and non-invasive rhinosinusitis (8.1%)
and onychomycosis (8.1%). Immunosuppression is frequently associated with cutaneous and subcu-
taneous infections and rhinosinusitis. The most important risk factors for cutaneous and subcutaneous
infections are solid organ transplantation and Cushing’s syndrome, and those for rhinosinusitis are bone
marrow transplants. Having been exposed to soil and garbage is common in all cases of oculomycosis,
with corticotherapy being a risk factor in 50% of these cases. Previous contact with soil and ⁄ or trauma to
the nails is associated with most cases of onychomycosis. In general, alternariosis shows a good response
to conventional antifungal drugs. On some occasions, steroid suppression or reduction is sufficient to
resolve an infection. Itraconazole is the antifungal drug used most frequently to successfully treat
onychomycosis and cutaneous and subcutaneous infections. Posaconazole and voriconazole are
promising therapeutic options, with the latter being especially so for oculomycosis.
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INTRODUCTION
In the last two decades, fungal infections have
become an important cause of morbidity and
mortality, especially affecting immunocompro-
mised patients. Antibacterial treatment, bone
marrow and solid organ transplantation, chemo-
therapy and primary or acquired immunodefi-
ciency are conditions favourable for the
development of severe fungal infections [1].
Phaeohyphomycoses, which are opportunistic
infections caused by melanized (dematiaceous)
moulds [2], have acquired special relevance in
recent years. The incidence of these infections is
increasing, mainly in transplant centres [3,4].
Alternaria is a dematiaceous hyphomycete that is
frequently involved in human infection. Alternaria
is a very large and complex genus that encom-
passes hundreds of species, although specific data
are difficult to obtain because of the proliferation
of nomenclature of dubious taxonomic validity.
Alternaria has a worldwide distribution, with
many species being common saprophytes in soil,
air and a variety of other habitats; some are
ubiquitous agents of decay and plant pathogens
[5]. Alternaria can also be found on normal human
and animal skin [6] and conjunctiva [7]. This
fungus has been associated frequently with
hypersensitivity pneumonitis, bronchial asthma,
and allergic sinusitis and rhinitis [8–14]. How-
ever, it can also cause several different types of
human infections, e.g. paranasal sinusitis, ocular
infections, onychomycosis, cutaneous and subcu-
taneous infections [10], and, more rarely, granu-
lomatous pulmonary disease [15], soft palate
perforation [16] and disseminated disease
[17,18]. Occasionally, Alternaria has been reported
as a contaminant of soft contact lenses [19], and
has also been isolated from an emollient cream
[20]. Alternaria alternata has been (erroneously)
regarded as the most frequent species, followed
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by A. tenuissima, although identification to the
species level has not been performed on many
occasions [10].
This review considers all cases of alternariosis
reported in the literature up to 2007, with respect
to the main clinical manifestations, predisposing
factors, treatment and outcome. As species iden-
tification was not performed in the majority of the
reported cases, and the aetiological agent was
misidentified in many other cases, some guide-
lines for laboratory diagnosis are also included.
LABORATORY DIAGNOSIS
Morphology
Numerous cases of alternariosis have been attrib-
uted to A. alternata, A. tenuissima and other spe-
cies, when the actual causal agent was A. infectoria
[21]. The latter is the most common clinical
species, although its ability to sporulate in routine
media is very poor. This fact, in conjunction with
the lack of pigmentation of this species, makes its
identification difficult for non-experts. Until
recently, the identification of Alternaria isolates
was performed exclusively on the basis of mor-
phological criteria, with the most significant
characteristics being the morphology of the con-
idia and the formation (or not) of conidial chains.
The morphological characteristics useful for
distinction among the three species mentioned
above are the following: in A. alternata, the
conidia are medium-brown with a short,
cylindrical beak, and form long and profusely
branched chains (ten or more conidia); the conidia
of A. tenuissima are golden-brown, frequently
tapering gradually into a beak that is up to half
the length of the conidium, and occur commonly
in unbranched chains of three to five conidia; in
A. infectoria, the conidia are more scarce, as this
species usually sporulates poorly in common
media, with its conidia often becoming nearly
tubular and occurring in strongly branched
chains, with long, multiseptate secondary conid-
iophores often emerging (Fig. 1).
There has been anecdotal evidence of other
Alternaria spp. being found in clinical samples,
e.g. A. chlamydospora [22,23], A. longipes [24],
A. dianthicola [25] and several other, even less
common, species. These are easily distinguishable
by the formation of multicelled chlamydospores
in A. chlamydospora, conidia with only transversal
septa in A. longipes, and conidia with very long
beaks in A. dianthicola [5]. However, molecular
methods based on the analysis of internal tran-
scribed spacer (ITS) region sequences have dem-
onstrated that A. longipes and A. tenuissima cannot
be differentiated from A. alternata [21]. Therefore,
it seems probable that the only two species that
are isolated with any frequency in clinical sam-
ples are A. alternata and A. infectoria. The genus
Ulocladium is morphologically very close to Alter-
naria and has also been associated with clinical
infections, although more rarely [26–28].
50 µm
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Fig. 1. Morphology of conidia of:
(a) Alternaria alternata; (b) A. infecto-
ria; and (c) A. tenuissima.
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Ulocladium can be distinguished morphologically
from Alternaria because its young conidia are
attenuated at the base and the mature conidia
are broadly ellipsoidal, whereas the young
conidia in Alternaria are rounded at the base and
the mature conidia are obclavate and rostrate.
Upon histological examination, Alternaria
shows more or less irregular melanized hyphae
that are practically indistinguishable from many
other moulds that cause phaeohyphomycosis.
Culture is mandatory for the correct identifica-
tion of Alternaria spp., which grow in most
routine laboratory media, although the clinically
important species very soon lose their ability to
sporulate. In our experience, the most suitable
culture media for obtaining good sporulation of
isolates from clinical specimens is potato-carrot
agar.
Molecular identification
The use of molecular techniques facilitates the
identification of rare pathogenic fungi, such as
Alternaria spp., even by non-experts. Using the
Basic Local Alignment Search Tool (BLAST), it is
now easy to compare sequences of a given
unidentified fungus, even of a non-sporulating
strain, with those deposited previously in Gen-
Bank in order to find regions of similarity among
sequences. However, an important problem lies
in the fact that sequences within GenBank are
deposited without strict quality control concern-
ing species identification, and some sequences
have therefore been deposited under erroneous
names. In the case of Alternaria, it has been
estimated that c. 14% of the sequences deposited
in GenBank are misidentified [21]. Therefore,
although the method is useful, it is important to
ensure that unknown sequences are compared
with the sequences of reference strains that have
been identified by experts.
Amplification of the ITS region with pan-fungal
primers, included in the multicopy rRNA operon,
followed by downstream sequencing, has been
shown to be a useful method for identification of
Alternaria spp. Reliable ITS sequences of Alternaria
strains deposited in GenBank, which have been
checked by experts [21] and which are useful for
comparison, are: A. alternata AF229461, AF229460
and AF071394, and A. infectoria AF229458,
AF229480 and AJ2760558. In addition, De Hoog
and Horre´ [21] have provided a reliable procedure
to distinquish between Alternaria and Ulocladium
spp. of clinical interest, based on a PCR method
using general primers, followed by restriction
enzyme digestion of the amplicons. However,
the two predominant clinical species, A. alternata
and A. infectoria, can easily be differentiated
according to the length of the ITS1–4 amplicon,
with the ITS spacer domain being c. 570 bp in the
former species and c. 600 bp in the latter.
CLINICAL RELEVANCE
Alternaria infects mainly immunocompromised
hosts. Although infections in immunocompetent
hosts have also been reported, these rarely
involve invasive disease [29]. The portal of entry
of the infection is usually through corneal trauma
or breakdown of the skin barrier. The majority of
clinical manifestations involve cutaneous and
subcutaneous infections, although other types of
infections, e.g. oculomycosis, sinusitis, onycho-
mycosis and invasive disease, have also been
reported less commonly.
Ocular infections
The incidence of Alternaria spp. in oculomycosis
ranges from 3.3% to 10.4% [30–33]. However, this
can vary according to the geographical location,
and is probably related to the risk of trauma
caused by organic matter [33]. To date, 20 cases of
ocular infections caused by Alternaria spp. have
been reported. The patient characteristics, risk
factors, treatment and outcome are summarized
in supplementary Table S1. These cases were
reported from the USA (four cases) and another
nine countries, with one or two cases each. Male
patients accounted for 13 (65%) and females for
seven (35%) of the 20 cases. The median patient
age was 55 years, ranging from 29 to 82 years.
The majority of cases (65.0%) were cases of
keratitis (p = 0.02), although endophthalmitis was
also associated with four (20.0%) cases, and both
keratitis and concomitant endophthalmitis were
reported in three other cases (15.0%). In one case,
keratitis was associated with onychomycosis also
caused by Alternaria [34]. In general, patients were
farmers or gardeners, and had all been exposed to
soil and garbage. In many cases (55.5%), acciden-
tal or surgical ocular traumas were the predis-
posing factors. In two cases, the ocular injury was
suffered 2–6 years before presentation [35,36]. Six
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(30%) of the 20 patients had received therapy
with topical and ⁄ or systemic steroids. Five (25%)
patients had been treated previously with anti-
fungal agents. The causative agent was identified
as A. alternata in six cases and as A. infectoria in
one case. In the other cases, identification to the
species level was not reported.
Rhinosinusitis
Although Aspergillus is the most common mould
causing fungal sinusitis, other fungi, such as
Alternaria, can also be involved, albeit less
commonly, in such illnesses [37–40]. Seventeen
cases of invasive and non-invasive sinusitis
caused by Alternaria spp. have been reported
since 1977. Practically all of these cases were
reported from the USA. Another two cases were
reported as part of an epidemiological study on
paranasal sinus mycoses in India, but specific
clinical data for these infections were not
included [40]. The patient characteristics, risk
factors, treatment and outcome of these cases are
summarized in supplementary Table S2. The age
of the patients ranged from 13 to 56 years
(median 35.6). Male patients accounted for ten
(58.8%) and females for seven (41.2%) of the 17
cases. Immunosuppression was not a significant
risk factor (p = 0.09) for rhinosinusitis caused by
Alternaria, although this condition was present in
12 (70.6%) patients. Neutropenia was a common
factor in ten of these 12 patients, who suffered
from haematological malignancies, e.g. acute or
chronic myeloid or lymphoblastic leukaemia
(7 ⁄ 10), aplastic anaemia (1 ⁄ 10), Hodgkin’s lym-
phoma (1 ⁄ 10) or solid tumour (1 ⁄ 10). Seven
patients were bone marrow transplant recipients.
The other two immunocompromised patients
underwent topical and ⁄ or systemic steroid treat-
ment. The infection was invasive in 13 (76.5%) of
the 17 cases. A. alternata was isolated in four
cases and A. geophila in one case; in the remain-
ing cases, the aetiological agents were not iden-
tified to the species level.
Onychomycosis
The incidence of Alternaria as a causative agent of
onychomycosis is low, ranging from 0.08% to
2.5% in various epidemiological studies [41–43].
However, no detailed clinical data concerning
these cases have been reported. To date, only 17
cases of nail infections due to Alternaria spp. have
been reported, with most of the patients being
from Italy (10 ⁄ 17), followed by India (3 ⁄ 17) and
several other countries [34,44–50]. The median
patient age was 51.7 years, ranging from 7 to
76 years. Male patients accounted for 11 (64.7%)
and female for six (35.3%) of 17 patients. As with
onychomycosis caused by other fungi, a history of
contact with soil or trauma in the nails existed in
most of these cases. Two patients were diabetic
[44,49] and two were receiving steroid treatment
[34,49]. Clinical manifestations included dystro-
phy and distal subungual hyperkeratosis or ony-
cholysis. No significant difference (p = 0.439) was
found between the involvement of fingernails or
toenails. The former were involved in nine
(52.9%) of the cases, six of which affected more
than one nail, and the latter were involved in
seven (41.2%) cases, three of which affected more
than one nail. Both fingernails and toenails
were affected in one patient. Identification to the
species level was reported in 14 cases, with
A. alternata being isolated in 11 cases [45–47,49],
and A. humicola, A. pluriseptata and A. chlamydos-
pora in one case [44,49].
Cutaneous and subcutaneous infections
Skin is the most frequent site of infection due to
Alternaria spp., with 156 cases of skin infection
being reported to date (supplementary Table S3).
Cutaneous infections are significantly more
frequent than subcutaneous infections (88.4% vs.
5.8%, p <0.001). Cutaneous and concomitant sub-
cutaneous infections were both reported in
nine (5.8%) cases. Most cases were from Medi-
terranean countries, i.e. France (38), Spain (35),
Italy (15) and Greece (five). The median patient
age was 53.9 years, ranging from 6 months to
94 years. These infections were clearly more
frequent in males than in females (64.9% vs.
35.1%, p <0.001), which may be explained by the
fact that outdoor work is carried out more
frequently by males, bringing with it an increased
risk of minimal skin trauma [51]. Predisposing
factors were described in >50% of the reported
cases (128 ⁄ 156), with transplantation being the
most common risk factor (51 ⁄ 128, p <0.001).
Among those cases, 47 involved solid organs
and four involved bone marrow. Cushing’s syn-
drome was diagnosed in ten non-recipient trans-
plant patients (10 ⁄ 77, p <0.001). The remaining
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patients with predisposing factors (67 ⁄ 128,
p <0.001) were receiving immunosuppressive
therapy.
The cases of cutaneous and subcutaneous
alternariosis show a range of clinical manifesta-
tions. Most patients presented with erythema and
desquamation of skin, or with red papules that
developed to erosion and ulceration, particularly
after steroid treatment. When the infection was
associated with a penetrating trauma, clinical
manifestations in the skin usually corresponded
to a unilocular livid red plaque with central
ulceration, which sometimes developed into a
crust-ulcerous lesion, and usually affected previ-
ously healthy patients. A multilocular form of
disease, with papulonodular lesions or cutaneous
nodules, usually painless, was generally associ-
ated with disseminated alternariosis [52]. The
most frequently isolated species was A. alternata,
accounting for 59 (37.8%) of the 156 cases,
followed by A. tenuissima (23 cases, 14.7%), A.
infectoria (11 cases, 7.1%), A. chartarum and A.
chlamydospora (two cases each), and A. dianthicola,
A. longipes and A. stemphylioides (one case each).
Identification at species level was not reported in
the 55 remaining cases.
IN VITRO SUSCEPTIBILITY
Table 1 summarizes the scarce data available con-
cerning the in vitro antifungal susceptibility of
Alternaria. Isolates were not identified to the spe-
cies level in any of the four studies [53–56] that
included more than ten isolates. Amphotericin B
showed variable in vitro activity, with MICs rang-
ing from 0.032 to 16 mg ⁄L. The in vitro activity of
flucytosine against Alternaria spp. was practically
nil [24,53,57–63]. Among the azoles, fluconazole
showed no activity against Alternaria spp.
[24,53,61,64], whereas ketoconazole MICs varied
from £0.5 mg ⁄L [53,59,61,65,66] to ‡2 mg ⁄L
[45,53,62,64]. In general, itraconazole, voriconazole
and posaconazole showed good activity, with
MICs £0.5 mg ⁄L [54–56,67,68], although MIC90
values of >8 mg ⁄L have also been reported
[54,55]. Slightly lower activity has been reported
for ravuconazole, with MIC50 values of 1 mg ⁄L
[54,55]. Alternaria seems to be susceptible in vitro to
terbinafine [69] and to caspofungin [70], but resis-
tant to micafungin [71], although only very limited
data are available. As no comparative studies have
been performed, it is not known whether signifi-
cant differences exist between the antifungal
Table 1. In vitro susceptibility of Alternaria spp. to antifungal agents
Reference No. of isolates
Antifungal agent (MICs in mg ⁄L)
AMB 5FC FLC KCZ MCZ ITC VRC RVC PSC TBF MFG CSP
[10] 1a,b 0.25 – – – – 0.25 – – – – – –
[24] 1c,d 0.3 >322.7 40.0 1.6 2.5 0.24 – – – – – –
[45] 1a,b 3.0 10 – 3.0 – – – – – – – –
1b,e – 30 – 10 — – – – – – –
[53] 20d,f,g 0.12–16 >128 16 to >64 0.5–8.0 0.5–8.0 0.12–2.0 – – – – –
[54] 11d,f,h 0.25–0.50 – – – – 0.25 to >8 0.25 to >8 1.0 to >8 – – – –
[55] 11d,f,h 0.25–0.50 – – – – 0.25 to >8 0.25 to >8 1.0 to >8 0.12 to >8 – –
[56] 13d,f,h 0.50–4 – – – – 0.50–1.0 – – 0.125–0.25 – – –
[57] 1b,f 3.2 100 – – – – – – – – – –
[58] 1b,f 0.3 >200 – – 0.3 – – – – – – –
[59] 2b,i 0.2 >100 – 0.4 0.4 – – – – – – –
[60] 1a,d 1.0 >128 – – – 0.25 – – – – – –
[61] 1d,j 0.125 >64 64.0 0.5 – 0.125 0.5 – – – – –
[62] 1a,d 0.5 >128 – 2.0 – 0.5 – – – – – –
[63] 6a,k,l 0.3–1.2 >100 – – – – – – – – – –
[64] 1a,g 0.4 – 50.0 50.0 0.8 0.05 – – – – – –
[65] 1b,i – – – 0.5 – 0.05 – – – – –
[66] 1a,b 0.3 – – 0.1 – 0.07 – – – – – –
[67] 1j,m 0.032 – 16.0 – – 1.5 0.23 – – – – –
[68] 4d,f,l 0.5–4.0 – – – – 0.25–1.0 1.0–2.0 – – – –
[69] 1a,d – – – – – – – – 0.25 –
[70] 1f,g – – – – – – – – – – – £0.09
[71] 3a,d 0.5 – – – – £0.01 – – – – >8.0 –
[81] 1a,b 1.5 – – – – – – – – – – –
[82] 2b,f,l 1.2 to >10 – – – – – – – – – – –
[84] 1a,d 0.25 – – – – 8.0 – – – – – –
AMB, amphotericin B; 5FC, flucytosine; FLC, fluconazole; KCZ, ketoconazole; MCZ, miconazole; ITC, itraconazole; VRC, voriconazole; RVC, ravuconazole; PSC,
posaconazole; TBF, terbinafine; MFG, micafungin; CSP, caspofungin.
aAlternaria alternata. bSusceptibility method not reported. cAlternaria longipes. dMicrodilution broth method. eAlternaria chlamydospora. fAlternaria spp. gMacrodilution broth
method. hMIC50–MIC90.
iAlternaria tenuisima. jAlternaria infectoria. kAgar diffusion. lMIC range. mEtest.
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susceptibilities of the two most clinically common
Alternaria spp., i.e. A. alternata and A. infectoria.
TREATMENT AND OUTCOME
Ocular infections
Treatment and outcome of oculomycosis cases
caused by Alternaria are summarized in supple-
mentary Table S1. Various antifungal drugs
have been used in the treatment of these
infections, including topical, intravitreal and ⁄ or
systemic amphotericin B, flucytosine, topical
and oral fluconazole, topical ketoconazole, itrac-
onazole, and topical and oral voriconazole. On
most occasions, the infection was resolved
following antifungal therapy, but surgical
interventions, e.g. keratoplasty or vitrectomy,
were sometimes necessary. In two cases, treatment
and outcome were not described. In all but one
of the cases, the infection was resolved. In one
patient, the lesions persisted after antifungal
and surgical treatment, but the fungus did not
grow in culture [72]. Owing to the poor intra-
vitreal penetration of amphotericin B given
intravenously, intravitreal administration of this
antifungal drug after vitrectomy is indicated in
severe cases of fungal endophthalmitis [73].
Systemic and topical fluconazole can also be
used [73]. Voriconazole, administered orally
(400 mg twice daily), reaches concentrations of
0.81 and 1.13 mg ⁄L in vitreous fluid and aque-
ous humour, respectively, which correspond
approximately to the MIC90 values required for
most pathogenic fungi tested [74], including
Alternaria spp. [56]. In addition, the clinical
efficacy of voriconazole in keratitis caused by
Alternaria has recently been reported [75,76].
Thus, this drug appears to be a useful alterna-
tive to intravitreal or topical administration [77].
In addition, therapeutic intravitreal levels of
posaconazole were obtained after topical and
oral administration [78]. Although there is no
published clinical experience of the use of
posaconazole to treat oculomycosis caused by
Alternaria, the in vitro activity [55,56] and the
clinical efficacy of this drug in treating ocular
infections caused by other fungi [78,79] suggest
that posaconazole could also be a therapeutic
alternative for keratitis and endophthalmitis
caused by Alternaria.
Rhinosinusitis
Treatments and outcomes of rhinosinusitis caused
by Alternaria are summarized in supplementary
Table S2. To date, amphotericin B has been the
antifungal agent used most frequently, either
alone or in combination with flucytosine and ⁄ or
rifampicin. In the majority of cases, treatment
with antifungal agents was combined with sur-
gery. In two patients with no immunological
impairment, the infection was recurrent despite
surgical and medical treatment [80,81]. All
patients were cured, with the exception of one
who relapsed [58] and two who died from other
causes [82].
Onychomycosis
Itraconazole was the drug used most frequently
for the treatment of onychomycosis, being admin-
istered to 12 (92.3%) of the 13 patients who
received antifungal therapy. In eight (72.2%)
patients, the infection was cured.
Cutaneous and subcutaneous alternariosis
As for the other clinical manifestations of
Alternaria infections, no standard treatment
exists for cutaneous and subcutaneous infec-
tions. The treatments and outcomes of the
reported cases are summarized in supplemen-
tary Table S3. In 21 (13.4%) of the 156 cases
reported, there are no data concerning treat-
ment. In three (2.22%) of the treated patients,
infection was resolved with physical proce-
dures, e.g. hyperbaric oxygen [83] or local heat
[29,84]. The infection was resolved in nine
(6.66%) cases following surgery, and suppres-
sion of steroids was sufficient for resolution
in four (2.96%) of the 135 cases in which
therapeutic details were provided. A variety of
antifungal drugs were also used to treat those
infections, including amphotericin B, azoles and
terbinafine. Since the 1990s, itraconazole has
been the antifungal drug most frequently used,
generally with a satisfactory outcome. Vorico-
nazole was used only on two occasions [85,86],
resolving one infection [86]. No clinical experi-
ence has been reported concerning the treatment
of cutaneous ⁄ subcutaneous alternariosis with
posaconazole.
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CONCLUSIONS
Although frequently associated with allergic
respiratory diseases, Alternaria is an opportunistic
pathogenic mould that causes mainly oculomy-
cosis, rhinosinusitis, onychomycosis, and cutane-
ous and subcutaneous infections, generally in
immunocompromised patients. A. alternata is the
species reported most frequently as causing the
different clinical manifestations of alternariosis,
although identification to the species level is not
often performed and the aetiological agent was
probably often misidentified. Occupational expo-
sure to soil and garbage, surgical and non-
surgical trauma and topical or systemic steroids
are predisposing factors for oculomycosis.
Although rhinosinusitis has also been described
in immunocompetent hosts, the majority of cases
involve immunocompromised patients, most of
whom have undergone bone marrow transplan-
tation. Contact with soil or trauma of the nails are
the most frequent predisposing factors for ony-
chomycosis caused by Alternaria spp., although
steroid treatment and diabetes should also be
considered as possible predisposing factors.
Immunosuppression is a common feature in
cutaneous and ⁄ or subcutaneous cases of alternar-
iosis, with most patients being solid organ trans-
plant recipients. Cushing’s syndrome has also
been reported as a predisposing factor in many
cases.
In general, Alternaria shows a good response
to conventional antifungal drugs. On some occa-
sions, steroid suppression or reduction may be
sufficient to resolve the infection. Surgery alone
has also been used successfully in some cases,
but has been used in many other cases in
combination with medical treatment. In general,
cases of alternariosis have responded well to
treatment with the older antifungal drugs, e.g.
amphotericin B, flucytosine, fluconazole, mico-
nazole and nystatin. Itraconazole is the antifun-
gal drug that has been used most frequently in
cases of onychomycosis and cutaneous and
subcutaneous infections, with generally satisfac-
tory results. Voriconazole could be a good
alternative, especially in cases of oculomycosis,
but further studies are required. On the basis of
its in vitro activity and pharmacokinetics, posa-
conazole also constitutes a promising therapeutic
option.
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